Introduction: Merck Secures Injunction Over Generic HIV Drug Patent Challenge

In August 2024, Merck Sharp & Dohme, LLC successfully concluded a pharmaceutical patent infringement action against generic drug manufacturer Hetero USA, Inc. and its affiliates, securing a consent judgment that includes a permanent injunction protecting five patents covering its HIV treatment ISENTRESS HD® (raltegravir, 600 mg). Filed in the U.S. District Court for the District of New Jersey on December 7, 2023, Case No. 2:23-cv-22954 resolved in just 259 days — a remarkably swift resolution in pharmaceutical patent infringement litigation.

The case exemplifies the continuing vitality of Hatch-Waxman ANDA litigation as a strategic tool for branded pharmaceutical companies defending blockbuster HIV treatment patents. For patent attorneys, IP professionals, and R&D teams operating in the generic drug space, this outcome offers important lessons about consent judgment mechanics, multi-patent portfolio assertion, and the strategic leverage of early settlement in pharmaceutical patent disputes.

Case Overview

The Parties

The Patents at Issue

This landmark case involved five U.S. patents covering the HIV treatment ISENTRESS HD® (raltegravir, 600 mg). This multi-patent portfolio approach — “stacking” compound, formulation, and use patents — is a hallmark of pharmaceutical Hatch-Waxman litigation strategy.

• • U.S. Patent No. 7,169,780 — Raltegravir compound chemistry
• • U.S. Patent No. 7,754,731 — Formulation-related claims
• • U.S. Patent No. 8,771,733 — Pharmaceutical composition claims
• • U.S. Patent No. 9,649,311 — Extended formulation protection
• • U.S. Patent No. 10,772,888 — Additional use/formulation coverage

Litigation Timeline and Procedural History

The 259-day resolution from filing to consent judgment is notably efficient. Average Hatch-Waxman patent litigations that proceed to trial routinely extend 24–36 months. The rapid conclusion here signals that settlement negotiations were likely initiated early — potentially even during the 30-month statutory stay period — suggesting Merck’s multi-patent assertion posture created sufficient litigation risk for Hetero to negotiate favorable exit terms rather than contest validity or infringement at trial.

The case was handled at the district court level (first instance), with no PTAB inter partes review or appeals proceedings reflected in the available record. The Honorable Claire C. Cecchi presided over the matter in the U.S. District Court for the District of New Jersey, a preeminent forum for pharmaceutical patent litigation.

The Verdict & Legal Analysis

Outcome: Consent Judgment With Permanent Injunction

On August 22, 2024, the court entered a Consent Judgment and Permanent Injunction by stipulation of the parties. Key operative provisions include:

• An express admission of infringement: The judgment states unambiguously that “the making, having made, using, selling, offering to sell, importing, or distributing the Hetero Product in or for the United States infringes the Licensed Patents.”
• A permanent injunction barring Hetero and all affiliates, successors, and assigns from infringing activities with respect to the EQ 600 product in the United States.
• Dismissal with prejudice of all claims, counterclaims, and affirmative defenses, without costs or attorneys’ fees to any party.
• Court retention of jurisdiction to enforce the Settlement Agreement and Consent Judgment.

Specific financial terms of the underlying Settlement Agreement were not publicly disclosed.

Verdict Cause Analysis

The infringement action arose under the Hatch-Waxman Act’s ANDA framework. Hetero’s filing of ANDA No. 218374 with a Paragraph IV certification constituted a statutory act of infringement, placing the burden on Hetero to either design around the asserted patents or challenge their validity.

The consent judgment’s explicit language — admitting infringement across all five Licensed Patents — is legally significant. Unlike many pharmaceutical settlements that resolve infringement claims through negotiated licensing terms without formal validity or infringement findings, this judgment contains a clear infringement acknowledgment. This strengthens Merck’s enforcement posture in potential future disputes with other ANDA filers targeting the same product.

The settlement structure — licensing provisions combined with an agreed entry date (the specific authorized entry date being governed by the confidential Settlement Agreement) — reflects standard Hatch-Waxman resolution mechanics. Hetero likely secured a negotiated market entry date in exchange for the infringement concession, though these terms remain confidential.

Legal Significance

The consent judgment establishes several important markers:

1. Multi-patent portfolio effectiveness: Merck’s assertion of five patents across compound, formulation, and use claim types created a complex, expensive invalidity challenge that likely deterred Hetero from pursuing full litigation.
2. Infringement admission as settlement currency: The explicit infringement admission, while legally binding, may have been exchanged for favorable commercial entry terms — a strategic calculation IP practitioners should evaluate carefully in similar negotiations.
3. Scope of injunction: The injunction extends to affiliates, successors, and assigns, providing Merck broad enforcement coverage across Hetero’s corporate structure.